| oxaliplatin / Generic mfg. |
NCT00642746: Erlotinib and Chemotherapy for 2nd Line Treatment (Tx) of Metastatic Colorectal Cancer (mCRC) |
|
|
| Terminated | 2 | 16 | US | Erlotinib, Tarceva, Fluorouracil, Leucovorin, Oxaliplatin, Irinotecan | OHSU Knight Cancer Institute, Genentech, Inc., OSI Pharmaceuticals | Metastatic Colorectal Cancer | 12/11 | 12/11 | | |
NCT00969033 / 2007-005675-34: CS-1008 Used With Irinotecan Versus Irinotecan Alone in Subjects With Metastatic Colorectal Carcinoma Who Failed First-line Treatment With Oxaliplatin |
|
|
| Terminated | 2 | 8 | Europe | CS-1008, irinotecan, Camptosar | Daiichi Sankyo, Inc. | Metastatic Colorectal Cancer | 12/11 | 12/11 | | |
NCT00743678: Neoadjuvant FOLFOX6 + Cetuximab in Patients With Colorectal Cancer and Unresectable Liver Metastasis |
|
|
| Completed | 2 | 73 | RoW | FOLFOX6/cetuximab | Samsung Medical Center | Colorectal Cancer, Unresectable Liver Metastasis | 01/12 | 06/12 | | |
NCT01077739 / 2009-012090-36: A Study of Avastin (Bevacizumab) With XELOX or FOLFOX in Patients With Metastatic Colorectal Cancer and Disease Progression Under First-line FOLFIRI and Avastin |
|
|
| Completed | 2 | 75 | Europe | fluorouracil (5FU), leucovorin, bevacizumab [Avastin], capecitabine [Xeloda], oxaliplatin | Hoffmann-La Roche | Colorectal Cancer | 01/12 | 01/12 | | |
NCT00177307: Safety and Efficacy Study Using Bevacizumab, Capecitabine and Oxaliplatin for Colorectal Cancer |
|
|
| Completed | 2 | 40 | US | Bevacizumab, Capecitabine 2500 mg/m2/d in two divided doses, (May be 2000 or 3000 mg/m2/d after interim analysis) Days 1-8, every 2 weeks Until disease progression or unacceptable toxicity, Oxaliplatin 85 mg/m2 IV q 2 weekly Until disease progression, unacceptable toxicity,, or Grade 3 neuropathy or cumulative dose of 1200 mg/m2, Capecitabine, Oxaliplatin | University of Pittsburgh, Genentech, Inc. | Cancer | 02/12 | 02/12 | | |
| Withdrawn | 2 | 0 | Canada | irinotecan, capecitabine, oxaliplatin (IXO) and bevacizumab | Ottawa Hospital Research Institute, Hoffmann-La Roche, Sanofi | Metastatic Colorectal Cancer | 02/12 | 02/12 | | |
NCT00721916: Randomized Phase II Study of SOL for Untreated Metastatic Colorectal Cancer |
|
|
| Completed | 2 | 107 | Japan | SOL(The combination therapy of S-1, Leucovorin, and Oxaliplatin), mFOLFOX6(The combination therapy of 5-FU, l-LV and Oxaliplatin) | Taiho Pharmaceutical Co., Ltd., Yakult Honsha Co., LTD | Colorectal Cancer | 03/12 | 05/12 | | |
| Completed | 2 | 54 | US, Europe, RoW | Regorafenib (Stivarga, BAY73-4506), Oxaliplatin, Folinic acid, 5-FU (mFOLFOX6) | Bayer | Colorectal Neoplasms | 03/12 | 06/14 | | |
|
NCT00677144: Oxaliplatin and S-1 (OS) Versus Oxaliplatin and Capecitabine (XELOX) for Advanced Colorectal Cancer |
|
|
| Completed | 2 | 88 | RoW | OS (oxalipaltin+S-1), Eloxatin, TS-1, XELOX (oxalipaltin+capecitabine), Xeloda | Hallym University Medical Center, Sanofi | Colorectal Neoplasm | 04/12 | 04/12 | | |
NCT01198548: High-Dose Cholecalciferol in Treating Patients Receiving Combination Chemotherapy and Bevacizumab as First-Line Therapy For Metastatic Colorectal Cancer |
|
|
| Terminated | 2 | 10 | US | leucovorin calcium, CF, CFR, LV, bevacizumab, anti-VEGF humanized monoclonal antibody, anti-VEGF monoclonal antibody, Avastin, rhuMAb VEGF, cholecalciferol, Calciol, Vitamin D3, fluorouracil, 5-fluorouracil, 5-Fluracil, 5-FU, oxaliplatin, 1-OHP, Dacotin, Dacplat, Eloxatin, L-OHP, pharmacological study, pharmacological studies | Roswell Park Cancer Institute, National Cancer Institute (NCI) | Stage IV Colon Cancer, Stage IV Rectal Cancer | 04/12 | 06/12 | | |
NCT00707889 / 2007-007081-38: Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer |
|
|
| Completed | 2 | 159 | US, Canada, Europe, RoW | ABT-869, bevacizumab, oxaliplatin, mFOLFOX6 regimen, folinic acid, fluorouracil | AbbVie (prior sponsor, Abbott), Genentech, Inc. | Advanced Colorectal Cancer, Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum | 05/12 | 05/12 | | |
|
|
| Completed | 2 | 171 | US, Europe, RoW | CT-011, FOLFOX | Medivation, Inc. | Metastatic Colorectal Cancer | 05/12 | 03/13 | | |
|
| Withdrawn | 2 | 0 | Canada | OXALIPLATIN (SR96669), 5-FLUOROURACIL (5-FU), LEUCOVORIN (LV), BEVACIZUMAB | Sanofi | Colorectal Neoplasms | 05/12 | 05/12 | | |
NCT00093379: Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer |
|
|
| Completed | 2 | 20 | US | Capecitabine, Xeloda, Oxaliplatin, Eloxatin, Radiation Therapy (XRT), XRT, RT, Radiotherapy | M.D. Anderson Cancer Center, National Cancer Institute (NCI) | Anal Cancer | 07/12 | 07/12 | | |
NCT01175291: FOLFOX/Bevacizumab +/- MK-0646 in Metastatic Colorectal Cancer |
|
|
| Withdrawn | 2 | 0 | US | MK-0646, oxaliplatin, leucovorin, 5-FU, Fluorouracil, bevacizumab, Placebo, 5-Fluorouracil | H. Lee Moffitt Cancer Center and Research Institute, Merck Sharp & Dohme LLC | Metastatic Colorectal Cancer | 07/12 | 07/12 | | |
NCT00755118: Lohp, 5-Fu/Lv and Bevacizumab, Alternative With Cpt-11, 5-Fu/Lv and Cetuximab In Metastatic Crc |
|
|
| Terminated | 2 | 24 | Europe | Oxaliplatin, Eloxatin, LoHP, 5-Fluorouracil, 5-FU, Leucovorin, LV, Bevacizumab, Avastin, Irinotecan, CPT-11, Campto, Cetuximab, Erbitux | University Hospital of Crete | Colorectal Cancer | 08/12 | 08/12 | | |
NCT01281761: Simvastatin + Cetuximab/Irinotecan in K-ras Mutant Colorectal Cancer (CRC) |
|
|
| Completed | 2 | 52 | RoW | cetuximab/irinotecan/simvastatin | Samsung Medical Center | Metastatic Colorectal Cancer | 09/12 | 12/12 | | |
|
|
NCT01157039: A Trial of Glutamine to Prevent Oxaliplatin Neurotoxicity and a Pharmacokinetic Analysis of Oxaliplatin |
|
|
| Withdrawn | 2 | 0 | Canada | Glutamine, L-glutamine | AHS Cancer Control Alberta, Cross Cancer Institute | Colorectal Carcinoma, Neoplasms, Colorectal, Colorectal Cancer, Colorectal Tumors, Metastasis | 09/12 | | | |
| Completed | 2 | 60 | RoW | Chemotherapy | Chinese University of Hong Kong | Metastatic Colorectal Cancer | 10/12 | 10/12 | | |
|
NCT01703910 / 2012-001307-20: Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic |
|
|
| Completed | 2 | 29 | Europe | Arm A chemotherapy, Capecitabine, Cisplatin, Cetuximab, Doxorubicin, Fluorouracil, Gemcitabine, Irinotecan, Topotecan, Mitomycin C, Oxaliplatin, Paclitaxel, Docetaxel, Pemetrexed, Raltitrexed, Sorafenib, Erlotinib, Vinorelbine, Dasatinib, Etoposide, arm B chemotherapy | Centro Nacional de Investigaciones Oncologicas CARLOS III, Hospital Universitario de Fuenlabrada, Grupo Hospital de Madrid, Apices Soluciones S.L. | Adenocarcinoma of Colon, Adenocarcinoma of Rectum, Metastatic Disease | 11/12 | 12/14 | | |
NCT00250835: Combination of Oxaliplatin, Capecitabine, and Celecoxib With Concurrent Radiation for Rectal Cancer |
|
|
| Terminated | 2 | 38 | US | Chemotherapy, Celecoxib, and Radiation, Celecoxib = Celebrex, Oxaliplatin = Eloxatin, Capecitabine = Xeloda | New Mexico Cancer Care Alliance | Rectal Cancer | 12/12 | 05/15 | | |
| Completed | 2 | 41 | RoW | External Beam Radiotherapy, Radiotherapy, RT, Oxaliplatin, Fluorouracil, Leucovorin, Surgical Resection | Trans Tasman Radiation Oncology Group, Trans Tasman Radiation Oncology Group (TROG) | Rectal Cancer | 12/12 | 12/12 | | |
NCT01409005: Gemcitabine-UFTE Chemotherapy in Refractory Colorectal Cancer |
|
|
| Completed | 2 | 41 | RoW | Gemcitabine and UFTE chemotherapy | Seoul National University Bundang Hospital, Seoul National University Hospital, SMG-SNU Boramae Medical Center, Yuhan Pharmaceutical Company, Jeil Pharmaceutical Company | Metastatic or Recurrent Colorectal Cancer, Refractory to Fluoropyrimidine, Oxaliplatin and Irinotecan, Salvage Chemotherapy | 02/13 | | | |
NCT01060007: Five Fractions of Radiotherapy Followed by Full Dose FOLFOX Chemotherapy as Preoperative Treatment for Rectal Cancer |
|
|
| Completed | 2 | 80 | US | External beam radiation, Oxaliplatin, Eloxatin, Leucovorin, 5-FU, Fluorouracil, Efudex, Capecitabine, Xeloda | Washington University School of Medicine | Rectal Neoplasms | 04/13 | 09/14 | | |
| Completed | 2 | 47 | Europe | Cetuximab, Erbitux, Irinotecan, Camptosar, Oxaliplatin, Eloxatin, UFT, Tegafur, Uracil | The Christie NHS Foundation Trust, Merck Sharp & Dohme LLC | Metastatic Colorectal Cancer | 05/13 | 05/13 | | |
|
| Completed | 2 | 25 | RoW | Bevacizumab, Avastin, Oxaliplatin, 5-FU, Radiotherapy | Sixth Affiliated Hospital, Sun Yat-sen University | Rectal Adenocarcinoma | 05/13 | 08/14 | | |
NCT00220051: A Phase II Study of Oxaliplatin Capecitabine and Pre-operative Radiotherapy for Patients With Locally Advanced and Inoperable Rectal Cancer |
|
|
| Completed | 2 | 109 | Europe | Oxaliplatin, Capecitabine, Pre operative radiotherapy, Surgical Resection | Royal Marsden NHS Foundation Trust | Rectal Cancer | | | | |
| Completed | 2 | 76 | US, Europe | Panitumumab, Vectibix, Ganitumab, AMG 479, Irinotecan | Amgen | Metastatic Colorectal Cancer | 07/13 | 07/13 | | |
| Completed | 2 | 25 | Europe | preoperative induction chemotherapy in combination with bevacizumab followed by combined radiochemotherapy with capecitabine, Xeloda (capecitabine), Avastin (bevacizumab), Oxaliplatin | Austrian Breast & Colorectal Cancer Study Group, Hoffmann-La Roche | Rectal Cancer | 08/13 | 08/13 | | |
NCT00321685: Bevacizumab, Radiation Therapy, and Combination Chemotherapy in Treating Patients Who Are Undergoing Surgery for Locally Advanced Nonmetastatic Rectal Cancer |
|
|
| Completed | 2 | 57 | US | Bevacizumab, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF rhuMAb, Avastin, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar QL 1101, BEVACIZUMAB, LICENSE HOLDER UNSPECIFIED, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, Capecitabine, Ro 09-1978/000, Xeloda, Fluorouracil, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Leucovorin Calcium, Adinepar, Calcifolin, Calcium (6S)-Folinate, Calcium Folinate, Calcium Leucovorin, Calfolex, Calinat, Cehafolin, Citofolin, Citrec, citrovorum factor, Cromatonbic Folinico, Dalisol, Disintox, Divical, Ecofol, Emovis, Factor, Citrovorum, Flynoken A, Folaren, Folaxin, FOLI-cell, Foliben, Folidan, Folidar, Folinac, Folinate Calcium, folinic acid, Folinic Acid Calcium Salt Pentahydrate, Folinoral, Folinvit, Foliplus, Folix, Imo, Lederfolat, Lederfolin, Leucosar, leucovorin, Rescufolin, Rescuvolin, Tonofolin, Wellcovorin, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669, Radiation Therapy, Cancer Radiotherapy, Irradiate, Irradiated, irradiation, Radiation, Radiotherapeutics, RADIOTHERAPY, RT, Therapy, Radiation, Therapeutic Conventional Surgery | National Cancer Institute (NCI) | Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v7, Stage III Rectal Cancer AJCC v7 | 08/13 | 02/19 | | |
|
NCT01478594 / 2011-003502-24: A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy |
|
|
| Completed | 2 | 265 | US, Canada, Europe, RoW | Tivozanib, AV951, ASP4130, Bevacizumab, Avastin, mFOLFOX6 | AVEO Pharmaceuticals, Inc. | Colorectal Cancer | 09/13 | 01/15 | | |
|
|
|
|
|
|
|
|
| Completed | 2 | 80 | Europe | 5-FU, Irinotecan, Leucovorin, Oxaliplatin, bevacizumab [Avastin] | Hoffmann-La Roche | Colorectal Cancer | 10/13 | 10/13 | | |
|
NCT00098787: Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer |
|
|
| Completed | 2 | 247 | US | bevacizumab, NSC 704865, RhuMAb VEGF, Recombinant Humanized Monoclonal Anti-VEGF Antibody, fluorouracil, 5-Fluorouracil, 5-FU, Adrucil, Efudex, irinotecan hydrochloride, Camptothecin-11, CPT-11, Camptosar, leucovorin calcium, Leucovorin, Wellcovorin' citrovorum factor, folinic acid, 5-formyl tetrahydrofolate, LV, LCV., Oxaliplatin, Eloxatin, trans-l-diaminocyclohexane oxalatoplatinum, cis-[oxalato(trans-l-1,2-diaminocyclohexane)platinum(II)]. | Eastern Cooperative Oncology Group, National Cancer Institute (NCI) | Colorectal Cancer | 11/13 | 04/15 | | |
SETICC, NCT01071655 / 2009-012562-31: Selecting Treatment in Colorectal Cancer:Capecitabine or 5-fluorouracil Selection to be Combined With Oxaliplatin or Irinotecan as First-line Chemotherapy in Advanced Colorectal Cancer |
|
|
| Completed | 2 | 195 | Europe | BVZ+XELOX or BVZ+XELIRI or BVZ+FUIRI or BVZ+FUOX, BVZ+XELOX | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD), Hoffmann-La Roche | Colorectal Cancer | 11/13 | 11/13 | | |
NCT00114231: Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Stage I Rectal Cancer |
|
|
| Completed | 2 | 90 | US | capecitabine, Given IV, oxaliplatin, neoadjuvant therapy, therapeutic conventional surgery, radiation therapy, irradiation, radiotherapy, therapy, radiation | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI) | Colorectal Cancer | 12/13 | 12/14 | | |
NCT02345746: Hepatic Arterial Infusion With FOLFOX Alone or in Combination With IV Chemotherapy in Colon Cancer With Liver Metastasis |
|
|
| Withdrawn | 2 | 0 | NA | Oxaliplatin, Eloxatin®, Folinic Acid, Leucovorin, 5-Fluorouracil, 5-FU | Western Regional Medical Center | Metastatic Colorectal Cancer | 12/13 | 12/13 | | |
NCT00959647: A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study |
|
|
| Completed | 2 | 19 | US | Vismodegib, Erivedge, GDC-0449, RO5450815, FOLFOX, FOLFIRI, Bevacizumab, Avastin | Genentech, Inc. | Ovarian Cancer, Basal Cell Carcinoma, Metastatic Colorectal Cancer | 01/14 | 01/14 | | |
| Completed | 2 | 97 | Europe | 5-FU, bevacizumab [Avastin], irinotecan, leucovorin, oxaliplatin | Hoffmann-La Roche | Colorectal Cancer | 02/14 | 02/14 | | |
|
|
NCT01399684 / 2011-001867-28: A Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and mFOLFOX-6 in Participants With Previously Untreated Metastatic Colorectal Cancer |
|
|
| Completed | 2 | 127 | US, Europe, RoW | 5-Fluorouracil, Bevacizumab, Folinic acid, MEGF0444A, Oxaliplatin, Placebo | Genentech, Inc. | Metastatic Colorectal Cancer | 02/14 | 02/14 | | |
NCT01226719: FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only |
|
|
| Completed | 2 | 15 | US | Panitumumab, Combined Modality Treatment, Oxaliplatin, Irinotecan, Leucovorin, 5-Fluorouracil | SCRI Development Innovations, LLC, Amgen | Colorectal Cancer | 03/14 | 03/14 | | |
|
NCT01378143: Using OCZ103-OS in Patients With Unresectable and Locally Recurrent or Metastatic Colorectal Cancer Undergoing Standard Chemotherapy |
|
|
| Completed | 2 | 53 | Canada | OCZ103-OS [pentamidine bis(2-hydroxyethanesulfonate)], mFOLFOX6 or FOLFIRI | Oncozyme Pharma Inc. | Colorectal Cancer | 03/14 | 07/14 | | |
APEC-Study, NCT00778830: Study Evaluating the Safety and Efficacy of FOLFIRI Plus Cetuximab or FOLFOX Plus Cetuximab as First-line Therapy in Subjects With KRAS Wild-type Metastatic Colorectal Cancer |
|
|
| Completed | 2 | 289 | RoW | Cetuximab, Erbitux, FOLFIRI, FOLFOX | Merck KGaA, Darmstadt, Germany, Merck Pte. Ltd., Singapore | Metastatic Colorectal Cancer | 04/14 | 04/14 | | |
|
|
|
|
|
| Completed | 2 | 77 | Europe | 5-Fluorouracil (5-FU), Bevacizumab, Avastin, Levofolinic acid, Oxaliplatin | Hoffmann-La Roche | Colorectal Cancer | 05/14 | 05/16 | | |
PRIMM, NCT01715363: Feasibility of an Immediate Preoperative Chemotherapy Before Resection fo Colorectal Cancer |
|
|
| Terminated | 2 | 3 | Europe | Oxaliplatin, Folinic Acid, Fluorouracile | Gustave Roussy, Cancer Campus, Grand Paris | Patients With Colorectal Cancer With Unresectable Synchronous Metastasis in Whom Resection of the Primitive Tumour is Indicated | 06/14 | 06/14 | | |
NCT00165854 / 2004-002597-33: Study of E7070 Combined With Capecitabine to Determine Efficacy and Recommended Dose of Combination in Patients With Metastatic Colorectal Cancer |
|
|
| Completed | 2 | 46 | Europe | E7070 | Eisai Limited | Colorectal Cancer (CRC) | | | | |
NCT00686166: S0713: Oxaliplatin, Capecitabine, Cetuximab, and RT Followed By Surgery in Pts W/Stage II or III Rectal Cancer |
|
|
| Completed | 2 | 83 | US | cetuximab, IMG-C225, Erbitux, NSC-714692, capecitabine, Xeloda, NSC-712807, oxaliplatin, Eloxatin, NSC-266046, therapeutic surgical procedure, Resection, radiation therapy, RT | Southwest Oncology Group, National Cancer Institute (NCI) | Colorectal Cancer | 07/14 | 03/18 | | |
|
| Completed | 2 | 78 | Europe | panitumumab | Hellenic Cooperative Oncology Group | Colorectal Cancer | 08/14 | 12/14 | | |
|
| Completed | 2 | 150 | Europe | Induction trichemotherapy - FOLFIRINOX regimen, Early tumor response evaluation by MRI volumetry, Radiochemotherapy Cap 50, Radiochemotherapy Cap 60, Radical proctectomy with total mesorectal excision | Institut du Cancer de Montpellier - Val d'Aurelle | Locally Advanced Malignant Neoplasm, Rectal Carcinoma | 09/14 | 09/14 | | |
| Terminated | 2 | 266 | US, Europe, RoW | Simtuzumab, SIM; GS-6624, Placebo to match SIM, Leucovorin, Folinic acid, Irinotecan, Fluorouracil | Gilead Sciences | Colorectal Cancer | 10/14 | 02/15 | | |
NCT01941953: Metformin and 5-fluorouracil for Refractory Colorectal Cancer. |
|
|
| Completed | 2 | 50 | RoW | Metformin and Fluorouracil | Instituto do Cancer do Estado de São Paulo | Metastatic Colorectal Cancer | 11/14 | 03/15 | | |
NCT01320683: Combination Chemotherapy and Bevacizumab Before Surgery and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer |
|
|
| Terminated | 2 | 1 | US | oxaliplatin, 1-OHP, Dacotin, Dacplat, Eloxatin, L-OHP, leucovorin calcium, CF, CFR, LV, fluorouracil, 5-fluorouracil, 5-Fluracil, 5-FU, bevacizumab, anti-VEGF humanized monoclonal antibody, anti-VEGF monoclonal antibody, Avastin, rhuMAb VEGF, yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A, laboratory biomarker analysis, pharmacological study, pharmacological studies, irinotecan hydrochloride, Campto, Camptosar, CPT-11, irinotecan, U-101440E | City of Hope Medical Center, National Cancer Institute (NCI) | Liver Metastases, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer | 12/14 | 12/14 | | |
| Completed | 2 | 24 | Europe | blood samples | Arbeitsgemeinschaft medikamentoese Tumortherapie | Metastatic Colorectal Cancer | 12/14 | 12/14 | | |
|
NCT01926769: A Phase II Study to Determine the Safety and Efficacy of Second-line Treatment With Metformin and Chemotherapy (FOLFOX6 or FOFIRI) in the Second Line Threatment of Advanced Colorectal Cancer |
|
|
| Terminated | 2 | 2 | RoW | Metformin | Gachon University Gil Medical Center | Previously Treated Advanced Colorectal Cancer | 12/14 | 12/14 | | |
| Completed | 2 | 80 | Europe | Panitumumab+FOLFOX-4, Panitumumab+FOLFIRI | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD), Amgen | Colorectal Cancer | 03/15 | 03/15 | | |
|
|
|
|
| Completed | 2 | 143 | Europe | folfoxiri+cetuximab+surgery+cetuximab, folfoxiri+cetuximab+surgery+bevacizumab | Gruppo Oncologico del Nord-Ovest | Metastatic Colorectal Cancer | 03/15 | | | |
|
|
NCT01269229: A Trial of Neoadjuvant FOLFOX6 With Short Course Radiotherapy in Patients With Unresectable Rectal Cancer and Liver Metastasis |
|
|
| Completed | 2 | 32 | RoW | folfox, short course Radiotherapy | Yonsei University | Rectal Cancer | 04/15 | 04/15 | | |
MAVERICC, NCT01374425 / 2011-004755-39: Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer (mCRC) |
|
|
| Completed | 2 | 376 | US, Canada, Europe | 5-Fluorouracil, Bevacizumab, Avastin, Irinotecan, Leucovorin, Oxaliplatin, Capecitabine | Genentech, Inc. | Colorectal Cancer | 05/15 | 07/15 | | |
|
|
|
MACRO-2, NCT01161316 / 2009-017194-38: Safety and Efficacy Study of mFOLFOX-6 Plus Cetuximab for 8 Cycles Followed by mFOLFOX-6 Plus Cetuximab or Single Agent Cetuximab as Maintenance Therapy in Patients With Metastatic Colorectal Cancer and WT KRAS Tumours |
|
|
| Completed | 2 | 194 | Europe | mFOLFOX-6 + cetuximab until disease progression or early withdrawal., 8 cycles of mFOLFOX-6 + cetuximab, followed by cetuximab alone until disease progression or early withdrawal. | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | Metastatic Colorectal Cancer | 06/15 | 06/15 | | |
|
|
NCT01882868: A Study of Aflibercept in Combination With FOLFIRI in Patients With Second-Line Metastatic Colorectal Cancer in Japan |
|
|
| Completed | 2 | 62 | Japan | Aflibercept, AVE0005, Levofolinate, Irinotecan, 5-FU | Sanofi, Regeneron Pharmaceuticals | Colorectal Cancer Metastatic | 08/15 | 08/15 | | |
| Terminated | 2 | 26 | Europe | CRS, Cytoreductive surgery, HIPEC, Hyperthermic intraperitoneal chemotherapy | University of Regensburg, Heinrich-Heine University, Duesseldorf | Peritoneal Carcinomatosis, Colorectal Cancer Metastatic | 09/15 | 10/17 | | |
NCT01749956: 5-FU, Aflibercept, and Radiation (RT) for Preoperative and Postoperative Patients With Stage II/III Rectal Cancer |
|
|
| Completed | 2 | 39 | US | Radiation, Aflibercept, Eylea, Zaltrap, Surgery, FOLFOX6, Leucovorin (Folinic Acid), 5-Fluorouracil (5-FU; Efudex), Oxaliplatin (Eloxatin) | SCRI Development Innovations, LLC, Sanofi | Rectal Cancer | 09/15 | 09/15 | | |
| Completed | 2 | 60 | Europe | Leucovorin, fluorouracil, leucovorin calcium, oxaliplatin, adjuvant therapy, neoadjuvant therapy, therapeutic conventional surgery, radiation therapy | Cardiff University, Cancer Research UK | Colorectal Cancer | 11/15 | 11/15 | | |
NCT01858662 / 2012-005249-19: Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Treatment Combining Cetuximab With FOLFOX or FOLFIRI in RAS and B-RAF WT Tumors |
|
|
| Terminated | 2 | 4 | Europe | Metastases Resection ( multiple steep surgery possible), 5-Fluorouracile, 5FU, leucovorin L, elvorine, isovorin, Oxaliplatin, Eloxatin, Irinotecan, Campto, Irinosin, Cetuximab, erbitux | Cliniques universitaires Saint-Luc- Université Catholique de Louvain, Grand Hôpital de Charleroi | Metastatic Colorectal Cancer | 11/15 | 11/15 | | |
REGAIN, NCT02316496: Rechallenge of Cetuximab Combined With Irinotecan as Third-line Chemotherapy in Patients With Metastatic Colorectal Cancer - Phase II Study |
|
|
| Terminated | 2 | 2 | Europe | cetuximab, Irinotecan | GERCOR - Multidisciplinary Oncology Cooperative Group | Colorectal Cancer Metastatic | 01/16 | 01/17 | | |
| Completed | 2 | 10 | Europe | Bevacizumab, Capecitabine, Irinotecan | Gustave Roussy, Cancer Campus, Grand Paris | Colorectal Neoplasms | 02/16 | 02/16 | | |
|
NCT02046538: Phase II Study of Zaltrap and Chemotherapy for Advanced Resectable Colorectal Cancer |
|
|
| Withdrawn | 2 | 0 | US | Leucovorin, Wellcovorin, Oxaliplatin, Eloxatin, 5-FU, Adrucil, fluorouracil, Irinotecan, Camptosar | Weill Medical College of Cornell University, Sanofi | Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum | 02/16 | 02/18 | | |
PREVIUM, NCT02175654 / 2014-000703-26: Regorafenib as Single Agent in Patients With Metastatic Colorectal Cancer (mCRC) With Any RAS or BRAF Mutation Previously Treated With FOLFOXIRI Plus Bevacizumab |
|
|
| Terminated | 2 | 15 | Europe | Regorafenib | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD), Bayer | Colorectal Neoplasms, Metastatic Disease | 02/16 | 02/16 | | |
| Completed | 2 | 186 | US, Europe, RoW | PledOx (2 µmol/kg), Calmangafodipir, PledOx (5 µmol/kg), PledOx (10 µmol/kg), Placebo (0,9% NaCl), Sodium chloride | Egetis Therapeutics, Pharma Consulting Group AB | Advanced Metastatic (Stage IV) Colorectal Cancer | 03/16 | 12/16 | | |
STEAM, NCT01765582: Sequential and Concurrent FOLFOXIRI/Bevacizumab Regimens Versus FOLFOX/Bevacizumab in First-Line Metastatic Colorectal Cancer |
|
|
| Terminated | 2 | 280 | US | 5-fluorouracil, bevacizumab, Avastin, capecitabine, Xeloda, irinotecan, folinic acid, leucovorin, oxaliplatin | Hoffmann-La Roche | Colorectal Neoplasms | 03/16 | 03/16 | | |
|
|
| Completed | 2 | 91 | Europe | Bevacizumab, Avastin, Oxaliplatin, Folinic Acid, 5-fluorouracil, Preoperative Radiotherapy, Surgery | Hoffmann-La Roche | Rectal Cancer | 03/16 | 03/16 | | |
|
NCT01889680: Safety and Effectiveness Study of Chemotherapy and Ziv-aflibercept to Treat Metastatic Colorectal Cancer |
|
|
| Withdrawn | 2 | 0 | US | 5-FU, 5-fluorouracil, LV, leucovorin, ziv-aflibercept, mFOLFOX6, 5-FU plus leucovorin plus oxaliplatin | NSABP Foundation Inc, Sanofi | Colorectal Cancer, Metastatic Colorectal Cancer | 05/16 | 05/18 | | |
NCT00571740: Cetuximab and Bevacizumab as First-Line Therapy Followed By Combination Chemotherapy and Bevacizumab With or Without Cetuximab as Second-Line Therapy in Treating Patients With Stage IV Colorectal Cancer |
|
|
| Withdrawn | 2 | 0 | RoW | bevacizumab, cetuximab, fluorouracil, leucovorin calcium, oxaliplatin | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI) | Colorectal Cancer | | | | |
NCT02085005: Capecitabine Plus Aflibercept as Maintenance Therapy Following Capecitabine Plus Oxaliplatin Plus Aflibercept in Patients With Metastatic Colorectal Cancer |
|
|
| Withdrawn | 2 | 0 | RoW | Capecitabine, Aflibercept AVE0005, Oxaliplatin SR96669 | Sanofi, Regeneron Pharmaceuticals | Colorectal Cancer Metastatic | 08/16 | 08/16 | | |
| Completed | 2 | 59 | Europe | Cetuximab, Erbitux® | Martin Schuler, Prof. Dr. med. | Metastatic Colorectal Cancer | 09/16 | 09/16 | | |
|
|
| Completed | 2 | 250 | Europe | Oxaliplatin, 5FU/LV, Bevacizumab, Bevacizumab, Oxaliplatin, I-LV, 5-FU, 5FU/LV, Oxaliplatin, Bevacizumab, Irinotecan, Irinotecan | Martin-Luther-Universität Halle-Wittenberg, Roche Pharma AG | Metastatic Colorectal Cancer | 09/16 | 08/18 | | |
| Terminated | 2 | 44 | Europe | FOLFOX6, Chemotherapy, Bevacizumab, Avastin, Panitumumab, Vectibix, Surgery | European Organisation for Research and Treatment of Cancer - EORTC, Amgen, Roche Pharma AG | Colorectal Cancer Metastatic, Liver Metastases, KRAS Wild Type Colorectal Cancer | 09/16 | 09/16 | | |
|
Be TRI, NCT02246049: A Multicenter, Clinical Study of FOLFOXIRI With Bevacizumab As First-line Therapy in Patients With mCRC |
|
|
| Completed | 2 | 69 | Japan | Bevacizumab, BV, 5-fluorouracil, 5-FU, Irinotecan hydrochloride, CPT-11, Leucovorin calcium, I-LV, Oxaliplatin, L-OHP | EPS Corporation | Colorectal Neoplasms | 02/17 | 02/17 | | |
| Completed | 2 | 232 | Europe | Maintenance:BEVACIZUMAB, Maintenance:BEVACIZUMAB+CAPECITABINE+CYCLOPHOSPHAMIDE | Azienda Ospedaliero, Universitaria Pisana | Metastatic Colorectal Cancer | 03/17 | 09/17 | | |
ATOM, NCT01836653: Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases |
|
|
| Completed | 2 | 122 | Japan | Bevacizumab, Avastin, Cetuximab, Erbitux, L-OHP, Oxaliplatin, l-LV, Levofolinate, 5-FU, Fluorouracil | EPS Corporation | Liver Only Metastasis From KRAS Exon 2 Wild Type (Under Protocol 1.0-1.2 Edition) and RAS Wild Type (Under Protocol 2.0 Edition) Colorectal Cancer | 03/17 | 03/17 | | |
NCT02026583: A Single Arm, Phase II Study of Simvastatin Plus XELOX and Bevacizumab as First-line Chemotherapy in Metastatic Colorectal Cancer Patients |
|
|
| Completed | 2 | 43 | RoW | Simvastatin | Samsung Medical Center | Colorectal Cancer | 04/17 | 04/17 | | |
NCT02079220: A Phase II Study of Ziv-aflibercept in Combination With Capecitabine/Oxaliplatin (XELOX) Chemotherapy in the Front-Line Treatment of Patients With Metastatic Colorectal Cancer |
|
|
| Withdrawn | 2 | 0 | US | Arm A, Xeloda, ELOXATIN, ZALTRAP, Arm B | James J Lee, Sanofi | Metastatic Colorectal Cancer | 03/18 | 03/18 | | |
VISNU-2, NCT01640444 / 2012-000840-90: Influence of BRAF and PIK3K Status on the Efficacy of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFIRI) Plus Bevacizumab or Cetuximab in Patients With RAS Wild-type Metastatic Colorectal Carcinoma and < 3 Circulating Tumor Cells (CTC) |
|
|
| Completed | 2 | 240 | Europe | FOLFIRI + bevacizumab, FOLFIRI + cetuximab | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD), Roche Pharma AG | Colorectal Cancer Metastatic | 11/18 | 11/18 | | |
| Recruiting | 2 | 100 | Europe | Bevacizumab plus alternating Xelox/Xeliri, Avastin, Xeloda, irinotecan, oxaliplatin | Pia Osterlund | Metastatic Colorectal Cancer | 12/25 | 12/25 | | |
NCT00625651: Phase 1b/2 Study of AMG 655 With mFOLFOX6 and Bevacizumab for First-Line Metastatic Colorectal Cancer |
|
|
| Completed | 1b/2 | 202 | US | Placebo, AMG 655, Modified FOLFOX6, mFOLFOX6, Bevacizumab | Amgen | Metastatic Colorectal Cancer, Colon Cancer, Colorectal Cancer, Rectal Cancer | 08/10 | 09/11 | | |
NCT00005050: Eniluracil, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Colorectal Cancer |
|
|
| Completed | 1/2 | | US | ethynyluracil, fluorouracil, oxaliplatin | NYU Langone Health, National Cancer Institute (NCI) | Colorectal Cancer | 06/01 | | | |
NCT00049101: Erlotinib and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer |
|
|
| Completed | 1/2 | | US | erlotinib hydrochloride, fluorouracil, leucovorin calcium, oxaliplatin | Memorial Sloan Kettering Cancer Center, National Cancer Institute (NCI) | Colorectal Cancer | | 08/04 | | |
NCT00055822: Combination Chemotherapy and Oblimersen in Treating Patients With Advanced Colorectal Cancer |
|
|
| Completed | 1/2 | 16 | US | oblimersen sodium, fluorouracil, leucovorin calcium, oxaliplatin | The University of Texas Health Science Center at San Antonio, National Cancer Institute (NCI) | Colorectal Cancer | 10/04 | 10/04 | | |
NCT00403624: Evaluation of the Neoadjuvant Treatment With Oxaliplatin -UFT- Radiotherapy in Rectal Cancer |
|
|
| Completed | 1/2 | 38 | Europe | OXALIPLATIN | Sanofi | Rectal Neoplasms | 11/05 | 11/05 | | |
NCT00087334: Capecitabine, Oxaliplatin, and Gefitinib in Treating Patients With Metastatic Colorectal Cancer |
|
|
| Terminated | 1/2 | 10 | US | capecitabine, gefitinib, oxaliplatin | Roswell Park Cancer Institute | Colorectal Cancer | 11/05 | | | |
| Terminated | 1/2 | 46 | Europe | Oxaliplatin | Sanofi | Rectal Neoplasms | 06/06 | | | |
NCT00006094: Oxaliplatin, Fluorouracil, and External-Beam Radiation Therapy Followed by Surgery in Treating Patients With Locally Advanced Cancer of the Rectum |
|
|
| Completed | 1/2 | 24 | US | oxaliplatin, 1-OHP, Dacotin, Dacplat, Eloxatin, L-OHP, fluorouracil, 5-fluorouracil, 5-Fluracil, 5-FU, external beam radiation therapy, EBRT | National Cancer Institute (NCI) | Adenocarcinoma of the Rectum, Stage II Rectal Cancer, Stage III Rectal Cancer | 10/06 | | | |
NCT00086931: Oxaliplatin, Capecitabine, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Rectum |
|
|
| Completed | 1/2 | 37 | US | capecitabine, oxaliplatin, conventional surgery, neoadjuvant therapy, radiation therapy | Roswell Park Cancer Institute | Colorectal Cancer | 05/07 | 05/10 | | |
CORGI, NCT01016639: Study of Capecitabine and Oxaliplatin in Combination With Radiotherapy in Patients With Unresectable Gastro-Intestinal Cancer |
|
|
| Completed | 1/2 | 106 | Europe | oxaliplatin, capecitabine, radiotherapy | Lund University Hospital, Roche Pharma AG, Sanofi-Synthelabo | Stomach Cancer, Gall Bladder Cancer, Bile Ductus Cancer, Pancreas Cancer, Colorectal Cancer | 07/07 | 07/09 | | |
NCT00291785: Phase I/II CT 2106 and 5-FU/FA in Colorectal Cancer |
|
|
| Completed | 1/2 | 48 | Europe | CT-2106, Folinic acid, 5-FU (fluorouracil) | CTI BioPharma | Colorectal Cancer | 08/07 | 09/08 | | |
SAKK 41/03, NCT00217711: Oxaliplatin, Irinotecan, and Capecitabine in Treating Patients With Advanced or Metastatic Colorectal Cancer That Cannot Be Removed By Surgery |
|
|
| Completed | 1/2 | 23 | Europe | Capecitabine, irinotecan hydrochloride, oxaliplatin | Swiss Group for Clinical Cancer Research | Colorectal Cancer | 08/07 | 10/11 | | |
NCT00226941: A Phase 1-2 Trial of Cetuximab in Combination With Oxaliplatin, Capecitabine, and Radiation Therapy Followed by Surgery for Locally-advanced Rectal Cancer |
|
|
| Terminated | 1/2 | 23 | US | Cetuximab, Erbitux, C225, IMC-C225, Oxaliplatin, Eloxatin, Capecitabine, Xeloda, Radiotherapy, XRT, Diphenhydramine hydrochloride (HCl), Benadryl, Unisom, Sominex | George Albert Fisher, Bristol-Myers Squibb | Rectal Cancer, Colo-rectal Cancer | 03/08 | 02/09 | | |
NCT00531245: A Phase I/II Trial of TS-1 and Oxaliplatin in Patients With Advanced Colorectal Cancer |
|
|
| Completed | 1/2 | 77 | RoW | TS-1, oxaliplatin | Samsung Medical Center | Colorectal Neoplasms | 06/08 | 03/09 | | |
NCT00422773: Safety of Cetuximab and Oxaliplatin/5-FU/FA/Irinotecan in First-Line Treatment of Metastatic Colorectal Cancer |
|
|
| Completed | 1/2 | 21 | Europe | Cetuximab, Cetuximab (C225, Erbitux by Merck) | Technische Universität Dresden | Metastatic Colorectal Cancer | 06/08 | | | |
|
NCT00345761: Clinical Study of Capecitabine, Oxaliplatin and Bevacizumab in Colorectal Cancer |
|
|
| Completed | 1/2 | 64 | Japan | Bevacizumab, Oxaliplatin, Capecitabine | Chugai Pharmaceutical, Yakult Honsha Co., LTD | Colorectal Cancer | 10/08 | 07/10 | | |
NCT00536809: Phase I/II Study of Lapatinib in Combination With Oxaliplatin and Capecitabine in Subjects With Advanced Colorectal Cancer |
|
|
| Completed | 1/2 | 12 | US | lapatinib, oxaliplatin, capecitabine | GlaxoSmithKline | Neoplasms, Colorectal | 10/08 | 10/08 | | |
